Lacosamide Tablet
Product Images NDC 50268-491

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 50268-491). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

50 (491 10)

Lacosamide Tablets USP 50 mg per tablet in a carton label by AvPAK. The label includes the product name, strength, and quantity of 100 tablets (10 x 10 unit dose). It specifies oral tablets with storage instructions and a barcode. The design is white with purple highlights and essential dispensing information.*

FDA Label Image

100 (492 10)

Packaging label for Lacosamide Tablets, USP 100 mg per tablet by AvPAK. The label states the medication is prescription only and includes storage instructions and dosage form as oral tablets. The package contains 100 tablets (10 x 10 unit dose) and features a barcode and space for overprinting GTIN, expiration date, lot, and serial number.*

FDA Label Image

Fig 3 (Figure 3)

A Kaplan-Meier survival curve graph comparing the proportion of patients over time (days) between a placebo group (PBO) and a Lacosamide group. The y-axis represents the proportion of patients, and the x-axis shows time in days. The graph includes patient risk numbers at various time points and statistical data indicating a significant difference (p-value = 0.001) with a hazard ratio (HR) of 0.548 and a 95% confidence interval.*

FDA Label Image

Fig1 (Figure1)

A bar chart showing median percent change from baseline in seizure reduction across three studies comparing placebo and various doses of Lacosamide tablets; Study 2 (200 mg, 400 mg, 600 mg), Study 3 (400 mg, 600 mg), and Study 4 (200 mg, 400 mg). Bars for Lacosamide doses show higher seizure reduction percentages with statistical significance indicated compared to placebo.*

FDA Label Image

Fig2 (Figure2)

This is a line graph comparing responder rates (equal to or greater improvement) versus percent of patients for Lacosamide tablets at different dosages (200 mg/day, 400 mg/day, 600 mg/day) and placebo. The graph shows responder rate on the vertical axis from -100% (worsening) to 100% (improvement) and percent of patients on the horizontal axis from 100% to 0%. Four lines represent placebo and each Lacosamide dosage.*

FDA Label Image

Str (Structure)

Chemical structure of lacosamide, showing its molecular framework with functional groups, including a phenyl ring, amide groups, and an ether linkage. This structure corresponds to the active ingredient lacosamide used in oral tablet dosage forms.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.